Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1998 Jul;78(1):96–99. doi: 10.1038/bjc.1998.448

Enzyme-linked immunosorbent assay of epidermal growth factor receptor in lung cancer: comparisons with immunohistochemistry, clinicopathological features and prognosis.

P Pfeiffer 1, E Nexø 1, S M Bentzen 1, P P Clausen 1, K Andersen 1, C Rose 1
PMCID: PMC2062940  PMID: 9662257

Abstract

The prognostic role of epidermal growth factor receptor (EGFR) remains controversial in patients with lung cancer. Previous assays for EGFR have primarily been qualitative or, at best, semiquantitative. In the present study, using fresh-frozen tissue from 190 unselected lung cancer patients, quantification of EGFR (EGFR(ELISA)) using a recently developed enzyme-linked immunosorbent assay (ELISA) technique was compared with results (EGFR(IHC)) obtained using immunohistochemistry (IHC). Correlation between results obtained by the two different techniques was highly significant (r(s) = 0.63, P < 0.001, n = 190). This correlation improved even further (r(s) = 0.76) when sections were estimated using an IHC score that took into account percentage staining, intensity and relative tumour area. Furthermore, the relationship between clinicopathological features and prognosis was identical for the two methods. The expression of EGFR was highest in squamous cell carcinomas, but it was not correlated with other characteristics such as age, sex, histological grading, stage or prognosis. We conclude that evaluation of EGFR content using IHC and ELISA produces comparable results.

Full text

PDF
96

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berger M. S., Gullick W. J., Greenfield C., Evans S., Addis B. J., Waterfield M. D. Epidermal growth factor receptors in lung tumours. J Pathol. 1987 Aug;152(4):297–307. doi: 10.1002/path.1711520408. [DOI] [PubMed] [Google Scholar]
  2. Christensen M. E., Engbaek F., Therkildsen M. H., Bretlau P., Nexø E. A sensitive enzyme-linked immunosorbent assay used for quantitation of epidermal growth factor receptor protein in head and neck carcinomas: evaluation, interpretations and limitations. Br J Cancer. 1995 Dec;72(6):1487–1493. doi: 10.1038/bjc.1995.534. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dawkins H. J., Robbins P. D., Sarna M., Carrello S., Harvey J. M., Sterrett G. F. c-erbB-2 amplification and overexpression in breast cancer: evaluation and comparison of Southern blot, slot blot, ELISA and immunohistochemistry. Pathology. 1993 Apr;25(2):124–132. doi: 10.3109/00313029309084784. [DOI] [PubMed] [Google Scholar]
  4. Dittadi R., Catozzi L., Gion M., Brazzale A., Capitanio G., Gelli M. C., Menegon A., Gardini G., Malagutti R., Piffanelli A. Comparison between western blotting, immunohistochemical and ELISA assay for p185neu quantitation in breast cancer specimens. Anticancer Res. 1993 Sep-Oct;13(5C):1821–1824. [PubMed] [Google Scholar]
  5. Dittadi R., Gion M., Pagan V., Brazzale A., Del Maschio O., Bargossi A., Busetto A., Bruscagnin G. Epidermal growth factor receptor in lung malignancies. Comparison between cancer and normal tissue. Br J Cancer. 1991 Oct;64(4):741–744. doi: 10.1038/bjc.1991.390. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hwang D. L., Tay Y. C., Lin S. S., Lev-Ran A. Expression of epidermal growth factor receptors in human lung tumors. Cancer. 1986 Nov 15;58(10):2260–2263. doi: 10.1002/1097-0142(19861115)58:10<2260::aid-cncr2820581017>3.0.co;2-u. [DOI] [PubMed] [Google Scholar]
  7. Mountain C. F. The new International Staging System for Lung Cancer. Surg Clin North Am. 1987 Oct;67(5):925–935. doi: 10.1016/s0039-6109(16)44330-6. [DOI] [PubMed] [Google Scholar]
  8. Nugent A., Gallagher J., Dolan J., O'Higgins N., Duffy M. J. Assay of the c-erbB-2 oncogene encoded protein by ELISA and immunocytochemistry in human breast cancer. Ann Clin Biochem. 1994 Mar;31(Pt 2):171–173. doi: 10.1177/000456329403100210. [DOI] [PubMed] [Google Scholar]
  9. Peto R., Pike M. C., Armitage P., Breslow N. E., Cox D. R., Howard S. V., Mantel N., McPherson K., Peto J., Smith P. G. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer. 1977 Jan;35(1):1–39. doi: 10.1038/bjc.1977.1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Pfeiffer P., Clausen P. P., Andersen K., Rose C. Lack of prognostic significance of epidermal growth factor receptor and the oncoprotein p185HER-2 in patients with systemically untreated non-small-cell lung cancer: an immunohistochemical study on cryosections. Br J Cancer. 1996 Jul;74(1):86–91. doi: 10.1038/bjc.1996.320. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Piffanelli A., Dittadi R., Catozzi L., Gion M., Capitanio G., Gelli M. C., Brazzale A., Malagutti R., Pelizzola D., Menegon A. Determination of ErbB2 protein in breast cancer tissues by different methods. Relationships with other biological parameters. Breast Cancer Res Treat. 1996;37(3):267–276. doi: 10.1007/BF01806508. [DOI] [PubMed] [Google Scholar]
  12. Prigent S. A., Lemoine N. R. The type 1 (EGFR-related) family of growth factor receptors and their ligands. Prog Growth Factor Res. 1992;4(1):1–24. doi: 10.1016/0955-2235(92)90002-y. [DOI] [PubMed] [Google Scholar]
  13. Robertson K. W., Reeves J. R., Smith G., Keith W. N., Ozanne B. W., Cooke T. G., Stanton P. D. Quantitative estimation of epidermal growth factor receptor and c-erbB-2 in human breast cancer. Cancer Res. 1996 Aug 15;56(16):3823–3830. [PubMed] [Google Scholar]
  14. Stanton P., Richards S., Reeves J., Nikolic M., Edington K., Clark L., Robertson G., Souter D., Mitchell R., Hendler F. J. Epidermal growth factor receptor expression by human squamous cell carcinomas of the head and neck, cell lines and xenografts. Br J Cancer. 1994 Sep;70(3):427–433. doi: 10.1038/bjc.1994.322. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Veale D., Kerr N., Gibson G. J., Harris A. L. Characterization of epidermal growth factor receptor in primary human non-small cell lung cancer. Cancer Res. 1989 Mar 1;49(5):1313–1317. [PubMed] [Google Scholar]
  16. Veale D., Kerr N., Gibson G. J., Kelly P. J., Harris A. L. The relationship of quantitative epidermal growth factor receptor expression in non-small cell lung cancer to long term survival. Br J Cancer. 1993 Jul;68(1):162–165. doi: 10.1038/bjc.1993.306. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Volm M., Drings P., Wodrich W. Prognostic significance of the expression of c-fos, c-jun and c-erbB-1 oncogene products in human squamous cell lung carcinomas. J Cancer Res Clin Oncol. 1993;119(9):507–510. doi: 10.1007/BF01686458. [DOI] [PubMed] [Google Scholar]
  18. Volm M., Mattern J. Correlation between successful heterotransplantation of lung tumors in nude mice, poor prognosis of patients and expression of Fos, Jun, ErbB1, and Ras. Anticancer Res. 1993 Nov-Dec;13(6A):2021–2025. [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES